Insights

Gathering insights about Vaxxas…

Similar companies to Vaxxas

Vaxxas Tech Stack

Vaxxas uses 8 technology products and services including cdnjs, Cloudflare, Google Font API, and more. Explore Vaxxas's tech stack below.

cdnjs
Content Delivery Network
Cloudflare
Content Management System
Google Font API
Font Scripts
Modernizr
Javascript Libraries
jQuery
Javascript Libraries
HTTP/3
Miscellaneous
Windows Server
Operating Systems
PHP
Programming Languages

Media & News

Vaxxas, Inc. is developing High-Density Microarray Patch.
Vaxxas is developing its High-Density Microarray Patch (HD-MAP) technology, which offers a simple, patient-friendly alternative to traditional needle-based vaccination.
Oct 03, 2024 | biotechdispatch.com.au
Vaxxas, Inc. launches Phase I trial for H7N9 influenza vaccine.
Vaxxas launches Phase I trial for H7N9 influenza vaccine.
Sep 12, 2024 | www.clinicaltrialsarena.com
Research Australia partners with Vaxxas, Inc..
The national peak body for health and medical research and innovation, Research Australia has partnered with Australian biotech company, Vaxxas, to bring around 70 health innovators together with Government to identify policy solutions to support the uptake of Australian health innovations here at home.
Jul 05, 2024 | researchaustralia.org
Vaxxas, Inc. launched Vaccine microarray patch self on Oct 18th '23.
CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)-- Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced a publication in the journal Vaccine entitled " Vaccine microarray patch self-administration: An innovative approach to improve pandemic and routine vaccination rates."
Oct 19, 2023 | www.ibtimes.com.au
Brandon Capital invests into Vaxxas, Inc. $100M.
So far, Vaxxas has raised more than $100 million in equity funding from investors including One Ventures and Brandon Capital, as well as $140 million in non-dilutive funding from contracts with organisations such as the Bill and Melinda Gates Foundation and Merck.
Oct 08, 2023 | www.afr.com
OneVentures Pty invests into Vaxxas, Inc. $100M.
So far, Vaxxas has raised more than $100 million in equity funding from investors including One Ventures and Brandon Capital, as well as $140 million in non-dilutive funding from contracts with organisations such as the Bill and Melinda Gates Foundation and Merck.
Oct 08, 2023 | www.afr.com
Vaxxas, Inc. partners with International Vaccine Institute.
To combat this menace, Vaxxas has partnered with SK bioscience, a notable contributor to vaccine research and development, and the International Vaccine Institute (IVI) to develop an innovative typhoid vaccine.
Aug 30, 2023 | www.geneonline.com

Vaxxas's Email Address Formats

Vaxxas uses at least 1 format(s):

Vaxxas Email Formats	Example	Percentage
First@vaxxas.com	John@vaxxas.com	70%
FLast@vaxxas.com	JDoe@vaxxas.com	27%
FMiddleLast@vaxxas.com	JMichaelDoe@vaxxas.com	2%
F.Last@vaxxas.com	J.Doe@vaxxas.com	1%

Frequently Asked Questions

Where is Vaxxas's headquarters located?

Vaxxas's main headquarters is located at Brisbane, AU. The company has employees across 3 continents, including OceaniaNorth AmericaEurope.

What is Vaxxas's official website and social media links?

Vaxxas's official website is vaxxas.com and has social profiles on LinkedIn.

How much revenue does Vaxxas generate?

As of September 2024, Vaxxas's annual revenue reached $15M.

What is Vaxxas's SIC code NAICS code?

Vaxxas's SIC code is 2834 - Pharmaceutical Preparations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Vaxxas have currently?

As of September 2024, Vaxxas has approximately 142 employees across 3 continents, including OceaniaNorth AmericaEurope. Key team members include Chief Executive Officer: D. H.Chief Operating Officer: S. F.Chief Business Officer/General Counsel/Evp: D. D.. Explore Vaxxas's employee directory with LeadIQ.

What industry does Vaxxas belong to?

Vaxxas operates in the Biotechnology Research industry.

What technology does Vaxxas use?

Vaxxas's tech stack includes cdnjsCloudflareGoogle Font APIModernizrjQueryHTTP/3Windows ServerPHP.

What is Vaxxas's email format?

Vaxxas's email format typically follows the pattern of . Find more Vaxxas email formats with LeadIQ.

How much funding has Vaxxas raised to date?

As of September 2024, Vaxxas has raised $2.6M in funding. The last funding round occurred on Aug 23, 2023 for $2.6M.

Vaxxas

Biotechnology ResearchBrisbane, Australia51-200 Employees

Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will help the world in rethinking what's possible with vaccines.

Company Overview

Headquarters: Brisbane, AU
Website: vaxxas.com
SIC Code: 2834 - Pharmaceutical Preparations
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 51-200

Media & News

Funding & Financials

$2.6M
Vaxxas has raised a total of $2.6M of funding over 8 rounds. Their latest funding round was raised on Aug 23, 2023 in the amount of $2.6M.
$10M$50M
Vaxxas's revenue is in the range of $10M$50M

Funding & Financials

$2.6M
Vaxxas has raised a total of $2.6M of funding over 8 rounds. Their latest funding round was raised on Aug 23, 2023 in the amount of $2.6M.
$10M$50M
Vaxxas's revenue is in the range of $10M$50M

Company Leadership

D. H.
Chief Executive Officer
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
S. F.
Chief Operating Officer
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
D. D.
Chief Business Officer/General Counsel/Evp
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
A. F.
Chief Technology Officer
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
D. C.
Chief Financial Officer
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Employee Directory

A. C.
Owner
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
A. F.
Owner
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
B. F.
Farmers Insurance Agency Owner
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
D. C.
Chief Financial Officer
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
J. K.
Chairman
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Vaxxas and Millions of Other Companies
Sign up for full access to Vaxxas information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Go to Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Vaxxas

Crossject

Vaxess Technologies

Capsugel

Zosano Pharma

Profusa

Vaxxas Tech Stack

Media & News

Vaxxas, Inc. is developing High-Density Microarray Patch.

Vaxxas, Inc. launches Phase I trial for H7N9 influenza vaccine.

Research Australia partners with Vaxxas, Inc..

Vaxxas, Inc. launched Vaccine microarray patch self on Oct 18th '23.

Brandon Capital invests into Vaxxas, Inc. $100M.

OneVentures Pty invests into Vaxxas, Inc. $100M.

Vaxxas, Inc. partners with International Vaccine Institute.

Vaxxas's Email Address Formats

Frequently Asked Questions

Where is Vaxxas's headquarters located?

What is Vaxxas's official website and social media links?

How much revenue does Vaxxas generate?

What is Vaxxas's SIC code NAICS code?

How many employees does Vaxxas have currently?

What industry does Vaxxas belong to?

What technology does Vaxxas use?

What is Vaxxas's email format?

How much funding has Vaxxas raised to date?

Vaxxas

Company Overview

Media & News

Vaxxas, Inc. is developing High-Density Microarray Patch.

Vaxxas, Inc. launches Phase I trial for H7N9 influenza vaccine.

Research Australia partners with Vaxxas, Inc..

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?